// App-Quantinova.ai

: Heterogeneous Responses Among Ph+-B-ALLs to Imatinib with NRAS Mutant Being One Mechanism of Complete Resistance

Researchers

Presenter

  • Xiaoyu An

Principal Investigators

  • Jinping Liu

  • Na Wang

  • Di Wang

  • Liang Huang

  • Jie Cai

  • Demin Zhou

  • Henry Li

Medical Centers

  • Crown Bioscience Inc, san diego

  • Crown Bioscience, Inc., Beijing, China.

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of differentiation 45

  • GTPase Nras

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved